Skip to content
OpenCapital
Get started

Immunovant, Inc. IMVT Q3 2026 earnings

Reported February 6, 2026 · Before market open

Diluted EPS-$0.61Beat by $0.11
Revenue estimate$6.0M
EPS estimate-$0.72

Next report

Aug 10, 2026 (In 4 weeks)
EPS estimate-$0.66

Financials

Q3 2026

Income statement

See full
Net income-$110.6M+0.4%
EPS (diluted)-$0.61+19.7%

Balance sheet

See full
Cash & equivalents$994.5M+165%
Total equity$986.1M+180%
Total assets$1.1B+150%

Cash flow

See full
Operating cash flow-$92.3M+8.0%
CapEx--100%
Free cash flow-$92.3M+8.2%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$5.12B+40.9%

Returns & leverage

See full
Return on equity-69.3%-4.2pp
Current ratio15.7×+9.7×

Versus estimates

Diluted EPS

Q4 2026-$0.73Miss by $0.13
Q3 2026-$0.61Beat by $0.11
Q2 2026-$0.73Miss by $0.01Q1 2026-$0.60Beat by $0.09Q4 2025-$0.64Beat by $0.07Q3 2025-$0.76Miss by $0.03

Ask the moment Immunovant, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Immunovant, Inc. report Q3 2026 earnings?
Immunovant, Inc. (IMVT) reported Q3 2026 earnings on February 6, 2026 before market open.
What were Immunovant, Inc.'s Q3 2026 revenue and EPS?
Immunovant, Inc. reported diluted EPS of $-0.61 for Q3 2026.
Did Immunovant, Inc. beat estimates in Q3 2026?
EPS beat the consensus estimate of $-0.72 by $0.11.
How did Immunovant, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 19.7% from $-0.76.
Where can I find Immunovant, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001764013-26-000010) and the 10-Q periodic report (0001764013-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.